Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 agonist, which Lilly renamed mazisotine, recently came through a phase 2 ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly to recognize $1.57B in Q1 as acquired R&D charges Apr. 11, 2025 7:44 AM ET Eli Lilly and Company (LLY) Stock By: Dulan Lokuwithana, SA News Editor 1 Comment Play (1min) ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH By Nick Paul Taylor Feb 10, 2025 9:40am Eli Lilly MASH radiopharmaceuticals Licensing deals ...

Eli Lilly and Co. officially opened its new Lilly Seaport Innovation Center on Tuesday. Gary Higgins / Boston Business Journal 1 of 11 By Hannah Green – Reporter, Boston Business Journal Aug 13 ...

Eli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project creating 400 jobs.

In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money. Most drug ...

Along the corridors of Indianapolis-based Eli Lilly, NBP may not have the brand swagger of Trulicity or Mounjaro, but as the drugmaker eyes a rich menu of growth opportunities, the sturdy acronym ...